Skip to main content

Phibro Animal Health Corporation (PAHC)

New York Stock Exchange Healthcare Drug Manufacturers - Specialty & GenericView data quality →
49.9Fair

ValueMarkers Composite Index

Top 28%#32,095 of 44,707

DCF data not available

Piotroski
6/9
Neutral
Beneish
-2.12
Investigate
Altman
3.21
Safe
DCF Value
-
N/A
ROIC
10.7%
Adequate
P/E
26.2
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Phibro Animal Health Corporation (PAHC) — VMCI valuation read

Phibro Animal Health Corporation (PAHC) carries a VMCI composite of 50/100, 0 points below the Healthcare sector median of 50. Among mid-cap names, that gap places PAHC in the bottom third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The PAHC insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads PAHC trades at 22.0x earnings, 22% above the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 18.0% sits 8.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of 0.6x leaves covenant headroom, the line to track on Phibro Animal Health Corporation's next 10-Q.

PAHC rose 2.9% over the trailing 7 days, with a -2.4% read on a 30-day basis.

Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It operates in the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 2014 and is headquartered in Teaneck, New Jersey.

CEO: Jack Clifford Bendheim1,940 employeesUSwww.pahc.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in PAHC’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.